Listen

Press releases

Receive e-mail alerts

Internal link ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis
July 19, 2016 at 11:00 AM UTC
Internal link ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC
June 21, 2016 at 01:00 PM UTC
Internal link ProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation
June 01, 2016 at 11:00 AM UTC
Internal link ProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference
June 01, 2016 at 11:00 AM UTC
Internal link ProQR Announces Results for the First Quarter of 2016
May 18, 2016 at 11:00 AM UTC
Internal link ProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-110 for LCA10 at the 2016 ARVO Annual Meeting
April 25, 2016 at 08:00 PM UTC
Internal link ProQR Announces Annual Meeting of Shareholders
April 07, 2016 at 11:00 AM UTC
Internal link ProQR to Highlight a Growing Pipeline During a Research & Development Day and Present at the Barclays Global Healthcare Conference
March 01, 2016 at 12:00 PM UTC
Internal link ProQR Announces Results for the Fourth Quarter and Full Year 2015
February 17, 2016 at 12:00 PM UTC
Internal link ProQR to Present at the Leerink Partners Global Healthcare Conference
February 03, 2016 at 12:00 PM UTC
Internal link ProQR Announces R&D Day and Provides Update on Innovation Portfolio
November 30, 2015 at 12:00 PM UTC
Internal link ProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials
November 23, 2015 at 11:30 AM UTC
Internal link ProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-010 for Cystic Fibrosis at Two Upcoming Scientific Conferences
October 01, 2015 at 11:00 AM UTC
Internal link ProQR to Present at the Leerink Partners 4th Annual Rare Disease Roundtable
September 23, 2015 at 11:00 AM UTC
Internal link ProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment
September 14, 2015 at 11:00 AM UTC
Internal link ProQR Announces Results for the Second Quarter of 2015
August 19, 2015 at 11:59 AM UTC
Internal link ProQR Announces Enrollment Has Started in Global Phase 1b Study of QR-010 in Cystic Fibrosis Patients
June 26, 2015 at 11:54 AM UTC
Internal link ProQR to Present at the JMP Securities Life Science Conference
June 16, 2015 at 11:00 AM UTC
Internal link ProQR Therapeutics Announces Results for the First Quarter of 2015
May 21, 2015 at 11:00 AM UTC
Internal link ProQR Therapeutics Announces Annual Shareholder Meeting
April 29, 2015 at 11:00 AM UTC
Internal link ProQR to Present at Two Upcoming Investor Conferences in May
April 29, 2015 at 11:00 AM UTC
Internal link ProQR Therapeutics Announces Results for the Fourth Quarter and Full Year 2014
February 26, 2015 at 12:00 PM UTC
Internal link ProQR to Present at the 2015 Leerink Global Healthcare Conference
February 04, 2015 at 12:00 PM UTC
Internal link ProQR Therapeutics Announces Results for the Third Quarter of 2014
November 24, 2014 at 12:00 PM UTC
Internal link ProQR Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
September 23, 2014 at 05:37 PM UTC

Press releases

Internal link ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis

Internal link ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC

Internal link ProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation

Internal link ProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference

Internal link ProQR Announces Results for the First Quarter of 2016

Internal link ProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-110 for LCA10 at the 2016 ARVO Annual Meeting

Internal link ProQR Announces Annual Meeting of Shareholders

Internal link ProQR to Highlight a Growing Pipeline During a Research & Development Day and Present at the Barclays Global Healthcare Conference

Internal link ProQR Announces Results for the Fourth Quarter and Full Year 2015

Internal link ProQR to Present at the Leerink Partners Global Healthcare Conference

Internal link ProQR Announces R&D Day and Provides Update on Innovation Portfolio

Internal link ProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials

Internal link ProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-010 for Cystic Fibrosis at Two Upcoming Scientific Conferences

Internal link ProQR to Present at the Leerink Partners 4th Annual Rare Disease Roundtable

Internal link ProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment

Internal link ProQR Announces Results for the Second Quarter of 2015

Internal link ProQR Announces Enrollment Has Started in Global Phase 1b Study of QR-010 in Cystic Fibrosis Patients

Internal link ProQR to Present at the JMP Securities Life Science Conference

Internal link ProQR Therapeutics Announces Results for the First Quarter of 2015

Internal link ProQR Therapeutics Announces Annual Shareholder Meeting

Internal link ProQR to Present at Two Upcoming Investor Conferences in May

Internal link ProQR Therapeutics Announces Results for the Fourth Quarter and Full Year 2014

Internal link ProQR to Present at the 2015 Leerink Global Healthcare Conference

Internal link ProQR Therapeutics Announces Results for the Third Quarter of 2014

Internal link ProQR Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares